The Food and Drug Administration (FDA) has approved Sandoz‘s Glatiramer Acetate Injection, the first generic version of Teva‘s Copaxone.

Glatiramer Acetate Injection is an immunomodulator indicated to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis (MS), including those who have experienced a first clinical episode and have MRI features consistent with MS.

RELATED: Multiple Sclerosis Treatments

Glatiramer Acetate Injection will be available as a 20mg/1ml daily injection.

For more information call (800) 525-8747 or visit